Evidence map›Paper›PMID 40390484›Full record

ArticleJournal, genetic engineering & biotechnology2025

Immunoinformatics-driven design of a multi-epitope vaccine against nipah virus: A promising approach for global health protection.

Muhammad Aqib Shabbir, Ammara Amin, Ammarah Hasnain, Ayesha Shakeel, Ambreen Gul

Abstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Computational design of a novel chimeric multi-epitope vaccine against chlamydia trachomatis serovar a to prevent trachoma.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muhammad Aqib ShabbirDepartment of Biotechnology, Faculty of Biological Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan. Electronic address: aqibmirza67@gmail.com.
Ammara AminDepartment of Biotechnology, Faculty of Biological Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan.
Ammarah HasnainDepartment of Biotechnology, Faculty of Biological Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan.
Ayesha ShakeelDepartment of Biological Sciences, University of Chester, United Kingdom.
Ambreen GulDepartment of Biotechnology, Faculty of Biological Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study focuses on developing a multi-epitope vaccine against the highly pathogenic Nipah virus using immunoinformatics. It aims to design a vaccine targeting the viral nucleoprotein to elicit robust immune responses. The approach integrates epitope prediction, vaccine construction, and validation through computational tools to address the lack of effective vaccines and mitigate global health threats posed by Nipah virus outbreaks. Immunoinformatics approaches have been utilized for epitope prediction, focusing on B-cell and T-cell epitopes of the Nipah virus nucleoprotein. The multi-epitope vaccine was constructed using linkers and adjuvants to enhance immunogenicity. Structural refinement, molecular docking with human ephrin B2 receptor, and immune simulations were performed to validate the vaccine's stability, binding efficiency, and immune response potential. The designed multi-epitope vaccine exhibited high antigenicity (0.56), non-allergenicity, and non-toxicity. Docking analysis showed a strong binding affinity with the ephrin B2 receptor (binding energy: -920 kcal/mol). Immune simulations indicated significant immune responses with high IgG and IgM levels and memory B-cell activation. Population coverage analysis revealed a global coverage of 88.3 %, supporting its potential for broad immunization. The designed vaccine against the Nipah virus demonstrates promising antigenicity, stability, and strong binding with the ephrin B2 receptor. With global population coverage and a robust immune response, it holds potential for clinical development. Further experimental validation and in vitro studies are recommended to confirm its efficacy as a viable vaccine candidate for the Nipah virus.

Indexed as

Docking AnalysisEpitope PredictionImmunoinformaticsMulti-Epitope VaccineNipah Virus

Identifiers

PMID40390484
PMCPMC11987609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.